arXiv subjects

Ran Balicer

Publications and source records attributed to Ran Balicer.

4 recordsLinked to original sources

arXiv2026

Decision language models as affordable and rapid alternatives to LLM judges of clinical generative AI

Automated judges of clinical artificial intelligence (AI) outputs are necessary, but large language model (LLM) judges are costly and slow at scale. We compared Jev, a decision language model that returns structured judgments, with frontier and open-weight LLM judges in four use cases. On 118 pediatric answers, Jev's agreement with physicians' ordinal quality ratings (Gwet's AC2 0.50; expected score 0.53) matched or exceeded that of seven of 12 LLM judges, including frontier models, Claude Opus 5.5 (0.49) and GPT-6 (0.38). On physician-graded binary HealthBench criteria, Jev matched or exceeded four of six LLM judges. On MedHELM's open-ended tasks, Jev's agreement with a three-LLM jury approached or exceeded the jurors' internal agreement. On HealthBench Professional, Jev matched the benchmark's reference judge, GPT-5.4, on 91% of criteria (other judges, 91-93%). Frontier judges cost 73-294 times more than Jev and took 7-57 times longer. Jev may enable efficient clinical AI evaluation at scale.

cs.AI↗

arXiv2026

Agentic discovery of blood biomarker from distilled private health records

Routine complete blood counts (CBCs) could yield new biomarkers, but the private records needed to evaluate candidates cannot be shared with frontier language model agents that excel at discovery. We distilled the evidence held in the Clalit Health Services panel of over 5.4 million patients into a released scoring tool: for each of 13 immune-mediated diseases, a graph attention network was trained inside the data boundary to predict the case-control AUC of candidate CBC expressions, and only the trained weights were released. The tool grounds an agent's propose-score-refine loop in real-world data without exposing any patient data. In external validation, agent-discovered expressions improved on their literature-seeded starting points by a median of 4.18 AUC percentage points, and across three independent cohorts, reranking the candidates of three frontier research tools improved on their first choices in most comparisons, with gains that varied by cohort. The released scorer supports privacy-preserving biomarker hypothesis generation.

cs.AI↗

arXiv2026

An AI agent for treatment reasoning over a biomedical tool universe

Treatment reasoning underpins every therapeutic decision, integrating disease context, comorbidities, medications, contraindications, and evolving biomedical knowledge to select an appropriate therapy. It is inherently iterative: candidates are weighed against many constraints, revised as evidence emerges, and grounded in verifiable sources. Here we introduce ATHENA-R1, an AI agent for treatment reasoning across all FDA approved drugs since 1939, trained by reinforcement learning over a universe of 212 biomedical tools. At each step it identifies missing information, selects and runs relevant tools, and incorporates the evidence. To train it without human-annotated traces, we build a two-level self-learning framework: multi-agent systems construct the tools, tasks, and reasoning trajectories for supervised fine-tuning, then reinforcement learning with scientific feedback rewards reasoning quality (evidence gathering, grounded tool use, logical non-redundancy). Across five benchmarks of 3,168 drug reasoning tasks and 456 patient treatment cases, ATHENA-R1 outperforms language models and tool-use systems, reaching 94.7% accuracy on open-ended drug reasoning and 82.9% on treatment reasoning, 17.8 and 10.7 points above GPT-5. In blinded evaluations by experts from 28 rare disease organizations, it is preferred over reference models on all criteria, and physicians rated it favorably on complex hospitalized cardiovascular and infectious-disease cases. Adverse-event hypotheses it generated, tested in electronic health records from 5.4 million patients, reached adjusted odds ratios of 1.48-1.84, with no elevation among negative controls. Because it requires knowing what evidence to seek before concluding, treatment reasoning has long been hard for AI; we show it can be reframed as a learnable process of iterative evidence gathering that reinforcement learning can train AI to perform.

cs.AI↗

arXiv2026

What Does the AI Doctor Value? Auditing Pluralism in the Clinical Ethics of Language Models

Medicine is inherently pluralistic. Principles such as autonomy, beneficence, nonmaleficence, and justice routinely conflict, and such ethical dilemmas often sharply divide reasonable physicians. Good clinical practice navigates these tensions in concert with each patient's values rather than imposing a single ethical stance. The ethical values that large language models bring to medical advice, however, have not been systematically examined. We present a framework for auditing value pluralism in medical AI, comprising a benchmark of clinician-verified dilemmas and an attribution method that recovers value priorities directly from decisions. The ecosystem of frontier models spans physician-level value heterogeneity, and models discuss competing values in their reasoning (Overton pluralism) before committing to a decision. However, individual model decisions are near-deterministic across repeated sampling and semantic variations, failing to reproduce the distributional pluralism of the physician panel. Across benchmark cases, these consistent decisions reflect committed, systematic value preferences. While most model priorities fall within the natural range of inter-physician variation, some significantly underweight patient autonomy. A single LLM deployed without regard for its value priorities could amplify those priorities at scale to every patient it serves. Without explicit efforts to balance ethical perspectives with one or multiple models, these tools risk replacing clinical pluralism with a deployment monoculture.

cs.AI↗